Skip to content
CancerIndex

Publication

Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia.

Boyi Chen, Shenxian Qian

Annals of hematologySep 1, 2026PMID 42678527doi:10.1007/s00277-026-07264-x PMC13534206Journal ArticleReviewLetterpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260908-000003
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

The phase III BRUIN CLL-313 and CLL-314 trials have established pirtobrutinib, a noncovalent Bruton tyrosine kinase (BTK) inhibitor, as a candidate for first-line therapy in chronic lymphocytic leukemia (CLL), and all-lines regulatory approval has now been granted in the European Union. We…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.